Our findings are generally consistent with those from the diabetes subanalysis of the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial) [7, 8]. Here, F10 is linked to atrial fibrillation.